Tislelizumab

精彩内容 米内网数据显示，2025上半年中国县级公立医院市场药品销售额约1300亿元，同比下滑6.72%，其中化药占比超过65%，中成药占比超过21%，生物药占比超过13%。化药及生物药四大品类市场份额均超10%，TOP20品牌中，5个品牌均大卖6亿元以上；中成药以心脑血管疾病用药为主，TOP20品牌中，以岭、步长、济川领跑。 近年来中国县级公立医院市场药品销售趋势（单位：亿元） 受集采深化冲击、基药制度引导、价格治理施压、监控药市场压缩以及创新药下沉相对不足等因素影响，我国县级公立医院药品市场正处阶段性调整期。米内网数据显示，其2024年销售规模超2687亿元，同比下滑6.13%；2025上半年继续以6.72%的降幅下滑至约1300亿元。 近年来中国县级公立医院市场药品类型格局 2025上半年药品类型格局方面，化药为主力军，市占比超过65%；中成药市占比超21%，呈逐年增长之势；生物药市占比超13%，近年来在11%-14%之间波动。 2025上半年中国县级公立医院市场化药及生物药大类格局 从化药及生物药大类格局上看，四个品类市场份额均在10%以上；其中消化系统及代谢药以超17%的市场份额排名第一，血液和造血系统药物、抗肿瘤和免疫调节剂均以超15%的份额排名第二和第三，全身用抗感染药物以超12%的份额排名第四。 2025上半年中国县级公立医院市场化药及生物药TOP20品牌 注：增长率不足3%用*表示 化药及生物药TOP20品牌中，阿斯利康的达格列净片、甲磺酸奥希替尼片和醋酸戈舍瑞林缓释植入剂包揽前三，信达生物的信迪利单抗注射液、石药集团的丁苯酞氯化钠注射液分别位列第四和第五。TOP5品牌销售额均超6亿元。 销售额增长率方面，13个品牌实现正增长，其中3个涨幅达两位数，具体为：百济神州的替雷利珠单抗注射液大涨53.56%、信达生物的信迪利单抗注射液大涨48.68%、诺华的沙库巴曲缬沙坦钠片大涨25.19%。 2025上半年中国县级公立医院市场中成药大类格局 从中成药大类格局上看，心脑血管疾病用药以超30%的市场份额遥遥领先，呼吸系统疾病用药、骨骼肌肉系统疾病用药分别以超14%和10%的份额位居其后。 2025上半年中国县级公立医院市场中成药TOP20品牌 注：增长率不足6%用*表示 中成药TOP20品牌中，青峰医药的喜炎平注射液、上海和黄药业的麝香保心丸、济川药业的蒲地蓝消炎口服液、天士力的复方丹参滴丸依次位列TOP1-TOP4，销售额均在3亿元以上；9个品牌销售额呈正增长，其中上海和黄药业的麝香保心丸涨幅达17.44%。 一级集团上榜情况方面，以岭药业有4个品种在列，分别是参松养心胶囊、通心络胶囊、连花清瘟颗粒和芪苈强心胶囊；步长制药有脑心通胶囊、丹红注射液、稳心颗粒3个品种上榜，济川药业（蒲地蓝消炎口服液、小儿豉翘清热颗粒）和华润医药（复方丹参滴丸、参附注射液）各有2个品种上榜。 资料来源：米内网数据库 注：米内网《中国县级公立医院药品终端竞争格局》，统计范围是：全国所有县（县级市）公立医院；上述销售额以产品在终端的平均零售价计算。 免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany. Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions. Details of the presentations are as follows: Abstract titlePresenter / Lead authorPresentation detailsSPONSORED STUDIES Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)Zhenhua Liu(Chengdu, China)2592MOMini Oral Session 1: GU tumours, renal & urothelialFriday, Oct 17, 2025Karlsruhe Auditorium - Hall 5.216:00 - 17:30 CESTA Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC)Stefan Kasper-Virchow (Essen, Germany)794P Poster Session:Colorectal cancerFruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 studyN. Arvind Dasari (Houston, USA)799PPoster Session:Colorectal cancerA novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC)Sara Lonardi (Padua, Italy)804PPoster Session:Colorectal cancerSafety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancerCathy Eng (Nashville, USA)811PPoster Session:Colorectal cancerAssociation between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 studyDanbo Wang (Shenyang, China)1230eP Poster Session:Gynaecological CancerctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)Yongfeng Yu (Shanghai, China)1954P Poster Session: NSCLC, metastaticSAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osiQuincy Siu-chung Chu (Edmonton, Canada)1955P Poster Session: NSCLC, metastaticMET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) studyJulia Rotow (Boston, USA)1956P Poster Session: NSCLC, metastatic INVESTIGATOR-INITIATED STUDIES Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trialFei Ma (Zhengzhou, China)2159P Poster Session: Oesophagogastric cancerFruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II StudyWangjun Liao (Guangzhou, China)898ePE-poster Session:Colorectal cancerThe efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical studyQianqian Wang (Nanjing, China)929P Poster Session: Developmental therapeuticsSurufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination RegimensYanfang Zheng(Guangzhou, China)1884PPoster Session:NSCLC, metastaticSurufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase II Results from a Single-Center TrialWenfeng Fang/ Li Zhang(Guangzhou, China)1887PPoster Session: NSCLC, metastaticEfficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancerSong Gao/ Jihui Hao(Tianjin, China)2236PPoster Session: Pancreatic cancerEfficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II StudyXiaowei Zhang/ Zhiguo Luo (Shanghai, China)2716PPoster Session: Sarcoma About Fruquintinib Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®. About Savolitinib Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®. About Surufatinib Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide. About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries+852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting –+44 20 3727 1030 / HUTCHMED@fticonsulting.comBen Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500 CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500 Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000